ELEKTA AB 2015-06-17
Hospital La Fe clinicians using Esteya® system achieve complete response among 100 percent of patients
Physicians at La Fe University and Polytechnic Hospital - Valencia presented their early clinical outcome data on the use of Esteya® electronic brachytherapy for the treatment of basal cell carcinoma in a paper in the current issue of Journal of Contemporary Brachytherapy. The ongoing study showed 100 percent complete response and excellent cosmetic outcome in all lesions treated to date with Esteya.
The paper, "Efficacy and safety of electronic brachytherapy for superficial and nodular basal cell carcinoma."1 is based on data from an ongoing, prospective clinical study.
The investigators conclude that Esteya electronic brachytherapy is a good treatment alternative for patients who are unsuitable for surgery, in addition to those who have declined surgery, have multiple lesions and for whom electronic brachytherapy might improve cosmetic outcome.
About Esteya
Elekta's Esteya electronic brachytherapy is a new, high-precision treatment solution for treating skin cancer. Esteya mimics high dose rate (HDR) brachytherapy by bringing a miniaturized x-ray source very close to the cancerous site, enabling the local application of radiation for effective treatment. With this direct delivery, Esteya can concentrate more therapeutic radiation to the disease target and minimize radiation to the surrounding tissues and organs. The compact design of the system, combined with high mobility, allows the treatment to occur virtually anywhere patients are seen.
1. J Contemp Brachytherapy 2015; 7, 3: DOI: 10.5114/jcb.2015.52140
|
distributed by
|
